Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Melanotan-1 Benefits: Research Comparison

Researchers selecting melanocortin peptides face a choice between Melanotan-1, Melanotan-2, and pharmaceutical afamelanotide (Scenesse). Each offers distinct pharmacological profiles and research applications. The table below compares receptor selectivity, hal

This comparison does not assign a generated winner or score.

  • Researchers selecting melanocortin peptides face a choice between Melanotan-1, Melanotan-2, and pharmaceutical afamelanotide (Scenesse). Each offers distinct pharmacological profiles and research applications. The table below compares receptor selectivity, half-life, typical research dosing, and primary study applications.
  • Melanotan-1
  • 100–1000× selective for MC1R over MC3R/MC4R
  • 2.5–3.5 hours subcutaneous
  • 0.5–2.0 mg/dose
  • Isolated melanogenesis studies, photoprotection mechanisms, MC1R binding assays
  • Best choice for studies requiring minimal confounding from appetite or metabolic effects—receptor selectivity allows attribution of effects specifically to MC1R pathway
  • Melanotan-2
  • 10–20× selective for MC1R; significant MC3R/MC4R activity
  • 1.5–2.5 hours subcutaneous
  • 0.25–1.0 mg/dose
  • Multi-receptor melanocortin studies, appetite/energy regulation, combined metabolic-pigmentation research
  • Appropriate when simultaneous melanocortin pathway activation is desired, but introduces confounding variables if isolating MC1R effects is the goal
  • Afamelanotide (Scenesse)
  • Identical to Melanotan-1
  • 2.0–3.0 hours; extended via implant formulation
  • 16 mg implant (releases over 60 days)
  • Clinical photoprotection studies, erythropoietic protoporphyria research
  • Pharmaceutical-grade standardization with regulatory approval, but implant delivery system limits dose flexibility for controlled experiments
  • Melanotan-1 demonstrates the highest MC1R selectivity in competitive binding assays, making it the preferred choice when research protocols require isolation of MC1R-mediated effects from the broader melanocortin system. The distinction matters most in controlled mechanistic studies where appetite suppression or erectile function changes would confound interpretation of melanogenesis data.
More references

Related material